Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 137 results for "ranbaxy laboratories"

Delhi HC tells Singh brothers to honour commitment to secure a...

NEW DELHI: Malvinder and Shivinder Singh, former promoters of Ranbaxy Laboratories, have a week to respond to the Delhi High Court on an application filed by Daiichi Sankyo, which is seeking to block the brothers from selling their assets. As ET ... Economic Times, 2 days ago

4 images for ranbaxy laboratories

Brief, 1 month ago
Yahoo! Finance, 1 month ago
Money Control, 3 months ago, 5 months ago

Delhi High Court accepts Daiichi Sankyo plea to block Fortis stake sale; next hearing on January 23

Daiichi Sankyo had acquired a majority stake in Indian drugmaker Ranbaxy Laboratories Ltd - promoted by the Singh brothers - for Rs
 Financial Express3 days ago Delhi High Court agrees to hear Daiichi Sankyo plea on January 23 seeking to block Fortis stake sale  Financial Express2 days ago
Post Online Media

Titan Pharmaceuticals Appoints Two New Board Members

By a News Reporter-Staff News Editor at Biotech Week - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura? long-term, continuous drug delivery ...
 Pharmacy Choice1 day ago TITAN PHARMACEUTICALS : Pharma Appoints Scott Smith and Dr. Rajinder Kumar to Board of Directors  4 Traders2 weeks ago Titan Pharma adds Scott Smith and Rajinder Kumar to board  Post Online Media2 weeks ago Titan Pharma Appoints Two New Board Members  BioSpace2 weeks ago

FiercePharmaAsia: Takeda, Valeant and more

Welcome to this week's FiercePharmaAsia report. Takeda announced two dealsat the J.P. Morgan Healthcare Conference—a $5.2 billion proposal to acquire Ariad and another one of $125 million to collaborate with Maverick on T-cell R&D. Valeant , in an ...
 FiercePharma6 days ago

Daiichi axes 170-person Indian R&D site

Daiichi Sankyo is to shutter its 170-person Indian R&D site. The Japanese drugmaker brought the site into its network in 2010 following its $4.6 billion acquisition of Ranbaxy Laboratories, but has now decided it can boost R&D productivity by axing ...
 FierceBiotech1 week ago

Takeda Pays 2012 Price For 2017-Model Ariad

Takeda's ( OTCPK:TKPHF ) ( OTCPK:TKPYY ) $5.2bn takeout of Ariad Pharmaceuticals dents the hypothesis that biotechs with declining valuations will be the chief M&A targets of 2017. Ariad's doubling in price over the course of 2016 defied ...
 Seeking Alpha1 week ago

Religare Enterprises' Singh brothers to go in for Divestment to save their diseased business

Malvinder Singh and Shivinder Singh of Fortis Healthcareare planning to divest management control in all their key businesses - hospitals, non-banking finance business, health insurance and stock broking - through multiple transactions that will ...
 India Infoline1 week ago Cash crunch-hit Singh brothers to cede key biz worth Rs 5,500 crore  Economic Times1 week ago FORTIS HEALTHCARE : Religare Enterprises' Singh brothers to go in for Divestment to save their diseased business  4 Traders1 week ago

Sun Pharma arm seeks USFDA nod for voluntary withdrawal of 28 ANDAs of Ranbaxy

These older drug products belong to erstwhile Ranbaxy Laboratories and are not being marketed in the US since 2008 The post Sun Pharma arm seeks USFDA nod for voluntary withdrawal of 28 ANDAs of Ranbaxy appeared first on Firstpost .
 First Post.com1 month ago Ranbaxy portfolio makes up for 37% of Sun's India sales  Smart Investor3 weeks ago BRIEF-Sun Pharmaceutical Industries announces voluntary withdrawal of 28 ANDAs  Reuters UK1 month ago Sun Pharma unit asks US FDA to withdraw nod for 28 drug applications of Ranbaxy  Business Today India1 month ago
Yahoo! Finance

AstraZeneca Plc (NYSE:AZN), Ranbaxy Laboratories Limited (NYSE:RBXLY) Wins Over Illegal Deal Case

The 1st US Circuit Court of Appeals has recently ruled in favor of AstraZeneca Plc (NYSE:AZN) and Ranbaxy Laboratories Limited (NYSE:RBXLY) on a long-lasting class action lawsuit involving an illegal agreement between the two companies related to ...
 4 Traders1 month ago AstraZeneca PLC (ADR) (AZN), Ranbaxy Laboratories Limited (ADR) (RBXLY) Wins Over Illegal Deal Case  InsiderMonkey.com1 month ago
Yahoo! UK and Ireland

U.S. court upholds AstraZeneca, Ranbaxy win in Nexium antitrust trial

By Brendan Pierson (Reuters) - A U.S. appeals court upheld AstraZeneca Plc and Ranbaxy Laboratories' victory in a lawsuit accusing them of reaching an illegal deal to delay the launch of a generic version of AstraZeneca's heartburn drug Nexium. ...
 Yahoo! UK and Ireland1 month ago ASTRAZENECA : U.S. court upholds AstraZeneca, Ranbaxy win in Nexium antitrust trial  4 Traders1 month ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less